Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 8:10:679.
doi: 10.1186/1471-2458-10-679.

Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates

Fatma Al-Maskari  1 , Mohammed El-Sadig, Nicholas Nagelkerke
Affiliations

Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates

Fatma Al-Maskari et al. BMC Public Health. .

Abstract

Background: Diabetes mellitus (DM) is a major health problem in the United Arab Emirates (UAE) and is well recognized as a major and increasing burden to the country's resources due to its severe, long term debilitating effects on individuals, families and the society at large. The aim of the study was to estimate the direct annual treatment costs of DM and its related complications among patients in Al-Ain city, UAE.

Methods: A sample of 150 DM patients were enrolled during 2004-2005, and their medical costs over the ensuing 12 months was measured, quantified, analyzed and extrapolated to the population in Al-Ain and UAE, using conventional and inference statistics. The costs were converted from UAE Dirhams to US Dollar, using the official conversion rate of US$ (1 USD = 3.68 AED).

Results: The total annual direct treatment costs of DM among patients without complications in Al Ain-UAE, was US $1,605 (SD = 1,206) which is 3.2 times higher than the per capita expenditure for health care in the UAE (US$ 497) during 2004 (WHO, 2004). However, this cost increased 2.2 times with the presence of DM related complications for patients with microvascular complications, by 6.4 times for patients with macrovascular complications and 9.4 times for patients with both micro and macrovascular complications. Likewise, the annual direct hospitalization costs of DM patients increased by 3.7 times for patients with microvascular complications, by 6.6 times for patients with macrovascular complications and by 5 times for patients with both micro and macrovascualr complications. Overall, costs increased with age, diabetes duration and were higher for patients treated with insulin compared to those treated with oral hypoglycemic agents or with diet control only.

Conclusions: DM direct treatment costs increased with the presence and progression of chronic DM related complications. Hospitalisation costs constituted a large proportion and were increasingly higher with the presence and progression of DM related complications. To reduce the impact on healthcare resources, efforts should be made to prevent progression to DM complications, by implementing guidelines for diabetes care, screening for complications and better management.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of DM Complications on the Average Cost per Patient in the UAE during 2004 (n = 150).
Figure 2
Figure 2
Effect of DM Complications on Hospitalization Cost per Patient in the UAE during 2004 (n = 150).
See this image and copyright information in PMC

References

    1. IDF Diabetes Atlas. Fourth. International Diabetes Federation; 2009. http://www.eatlas.idf.org/Costs_of_diabetes/Calculated_cost_estimates Cost of diabetes: calculated cost estimates.
    1. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008;31(3):596–615. doi: 10.2337/dc08-9017. - DOI - PubMed
    1. Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M, on behalf of the ARNO Working Group. The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutr Metab Cardiovasc Dis. 2010. - PubMed
    1. Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–12. doi: 10.1007/s00125-002-0858-x. - DOI - PubMed
    1. Malik M, Bakir A, Saab BA, King H. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract. 2005;69(2):188–95. doi: 10.1016/j.diabres.2004.12.005. - DOI - PubMed

Publication types